NXTC
NextCure Inc.
$10.51
+$1.30(+14.12%)
57
Overall
60
Value
54
Tech
--
Quality
Market Cap
$21.20M
Volume
42.44K
52W Range
$2.69 - $15.00
Target Price
$17.67
Company Overview
| Mkt Cap | $21.20M | Price | $10.51 |
| Volume | 42.44K | Change | +14.12% |
| P/E Ratio | -0.4 | Open | $9.44 |
| Revenue | -- | Prev Close | $9.21 |
| Net Income | $-55.7M | 52W Range | $2.69 - $15.00 |
| Div Yield | N/A | Target | $17.67 |
| Overall | 57 | Value | 60 |
| Quality | -- | Technical | 54 |
No chart data available
About NextCure Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest News
NextCure Raises $21.5M in Private Placement
TipRanks Auto-Generated Newsdesk•6 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NXTC | $10.51 | +14.1% | 42.44K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |